FILING ANALYSIS · TUESDAY, OCTOBER 27
Aclaris Therapeutics, Inc. ACRS — 8-K: Results of Operations and Financial Condition
positive
Aclaris Therapeutics reported positive primary analysis results from Phase 1b proof-of-concept trials of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 in atopic dermatitis and asthma, showing significant improvements in disease severity and symptoms, but the results are still preliminary and based on a small number of patients.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →